Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany

Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany

Introduction Among older adults, lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) is common. We evaluated the cost-effectiveness of bivalent RSV prefusion F protein-based vaccine (RSVpreF) for prevention of RSV-LRTI among older adults in Germany.Research design an...

Full description

Bibliographic Details
Main Authors: Ahuva Averin, Bennet Huebbe, Mark Atwood, Lea J Bayer, Caroline Lade, Christof von Eiff, Reiko Sato
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Expert Review of Vaccines
Subjects:
Respiratory syncytial virus
vaccine
bivalent respiratory syncytial virus prefusion F vaccine
RSVpreF
older adult
lower respiratory tract disease
Online Access:https://www.tandfonline.com/doi/10.1080/14760584.2024.2436183

Internet

https://www.tandfonline.com/doi/10.1080/14760584.2024.2436183

Similar Items